Cardiac Biomarkers Market, By Product Type (Myocardial Muscle Creatine Kinase, Myoglobin, Troponins, Brain Natriuretic Peptide or NT-proBNP, Ischemia-modified Albumin, and Others), By Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others), By Location of Testing (Laboratory Testing and Point of Care Testing), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jun 2024

Code : CMI4576

Pages :186

Formats :

Excel and PDF

Industry : Biotechnology

Market Concentration and Competitive Landscape

Cardiac Biomarkers Market Concentration By Players

Close-monitor your Competitor's Move, Request sample copy

Rising Focus on Innovation and Development of Novel Biomarkers

The growing focus of leading industry players and research institutions on innovation and development of novel cardiac biomarkers is another major factor fueling the growth of this market. Currently available biomarker tests only facilitate the detection of myocardial necrosis and injury. However, clinicians also require biomarkers that can provide accurate information on other aspects such as myocardial stress, ischemia, remodeling, and other pre-damage states. Therefore, newer biomarkers are being pursued that can enable the detection of cardiac abnormalities at early pre-damage stages as well. Considerable investments are being made for identifying novel biomarkers through omics-based techniques like proteomics and metabolomics. Some of the promising novel cardiac biomarkers in clinical trials or early stages of development include soluble ST2, galectin-3, matrix metalloproteinases, placental growth factor, ischemia-modified albumin, and others. The development of panels of multiple biomarkers is also gaining attention for facilitating comprehensive cardiac risk assessment. The pipeline of innovative biomarkers in the clinical development and approval phases will continue fueling market revenue in the coming years.

Key Players Insights